Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNTA NASDAQ:LEXX NASDAQ:MAAQ NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$0.63-0.2%$0.72$0.55▼$10.00$14.82M0.74721,182 shs17,137 shsLEXXLexaria Bioscience$0.61+0.0%$0.81$0.46▼$1.55$15.15M0.37191,479 shs3,578 shsMAAQMana Capital Acquisition$1.68-6.1%$2.48$5.35▼$10.25$13.65MN/A33,075 shs83,332 shsSHPHShuttle Pharmaceuticals$0.67+4.7%$0.86$0.50▼$6.19$3.73M0.382.28 million shs227,641 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science+7.36%-1.59%-1.75%-28.41%-85.30%LEXXLexaria Bioscience+1.41%-4.65%-40.11%-1.86%-42.37%MAAQMana Capital Acquisition-1.65%-1.65%-2.19%+38.76%-66.54%SHPHShuttle Pharmaceuticals-9.86%-9.34%-26.78%-42.34%-89.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNTAGenenta Science$0.63-0.2%$0.72$0.55▼$10.00$14.82M0.74721,182 shs17,137 shsLEXXLexaria Bioscience$0.61+0.0%$0.81$0.46▼$1.55$15.15M0.37191,479 shs3,578 shsMAAQMana Capital Acquisition$1.68-6.1%$2.48$5.35▼$10.25$13.65MN/A33,075 shs83,332 shsSHPHShuttle Pharmaceuticals$0.67+4.7%$0.86$0.50▼$6.19$3.73M0.382.28 million shs227,641 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNTAGenenta Science+7.36%-1.59%-1.75%-28.41%-85.30%LEXXLexaria Bioscience+1.41%-4.65%-40.11%-1.86%-42.37%MAAQMana Capital Acquisition-1.65%-1.65%-2.19%+38.76%-66.54%SHPHShuttle Pharmaceuticals-9.86%-9.34%-26.78%-42.34%-89.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNTAGenenta Science 1.00SellN/AN/ALEXXLexaria Bioscience 2.00Hold$1.50145.50% UpsideMAAQMana Capital Acquisition 0.00N/AN/AN/ASHPHShuttle Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SHPH, MAAQ, GNTA, and LEXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026SHPHShuttle Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/22/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/27/2026GNTAGenenta Science Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNTAGenenta ScienceN/AN/AN/AN/A$1.29 per shareN/ALEXXLexaria Bioscience$368K41.15N/AN/A$0.13 per share4.70MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$1.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNTAGenenta Science-$7.39MN/AN/AN/AN/AN/AN/AN/AN/ALEXXLexaria Bioscience-$11.90M-$0.47N/AN/AN/A-1,685.84%-206.02%-162.53%7/13/2026 (Estimated)MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/ASHPHShuttle Pharmaceuticals-$11.72M-$11.84N/AN/AN/AN/A-444.90%-188.81%N/ALatest SHPH, MAAQ, GNTA, and LEXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/13/2026Q2 2026LEXXLexaria Bioscience-$0.0950-$0.06+$0.0350-$0.06$0.05 million$0.02 million3/31/2026Q4 2025GNTAGenenta Science-$0.3641-$0.0750+$0.2891-$0.0750N/AN/A3/31/2026Q4 2025SHPHShuttle PharmaceuticalsN/A$0.06N/A$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNTAGenenta ScienceN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNTAGenenta Science0.3514.1614.16LEXXLexaria BioscienceN/A26.8426.84MAAQMana Capital AcquisitionN/AN/AN/ASHPHShuttle PharmaceuticalsN/A0.060.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNTAGenenta Science15.13%LEXXLexaria Bioscience13.06%MAAQMana Capital Acquisition68.44%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipGNTAGenenta Science28.99%LEXXLexaria Bioscience8.39%MAAQMana Capital AcquisitionN/ASHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNTAGenenta Science723.59 million16.75 millionNot OptionableLEXXLexaria Bioscience724.79 million22.71 millionNot OptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableSHPHShuttle Pharmaceuticals55.59 million4.89 millionNot OptionableSHPH, MAAQ, GNTA, and LEXX HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining RigsMay 14 at 4:05 PM | newsfilecorp.comNShuttle Pharmaceuticals Completes Merger and PIPE FinancingMay 7, 2026 | tipranks.comE.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin MinerMay 7, 2026 | globenewswire.comShuttle to Acquire United Dogecoin in Push to Build Public DOGE Mining PlatformMay 2, 2026 | finance.yahoo.comWhy is SHPH stock soaring today? Dogecoin mining pivot sparks rallyMay 2, 2026 | msn.comShuttle Pharmaceuticals Transforms into Dogecoin Mining PowerhouseMay 1, 2026 | tipranks.comUnited Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining OperationMay 1, 2026 | newsfilecorp.comNShuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin MinerApril 30, 2026 | newsfilecorp.comNRETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 27, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific WorkflowsMarch 26, 2026 | newsfilecorp.comNE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public OfferingMarch 12, 2026 | markets.businessinsider.comE.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public OfferingMarch 12, 2026 | globenewswire.comShuttle Pharmaceuticals Announces $3.5 Million Public OfferingMarch 6, 2026 | newsfilecorp.comNShuttle Pharma Extends Consulting Agreement With Interim Co-CEOFebruary 2, 2026 | tipranks.comUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | cantechletter.comCUtah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than EverJanuary 13, 2026 | newsfilecorp.comNShuttle Pharmaceuticals Accelerates Equity Payment in Asset DealDecember 29, 2025 | tipranks.comShuttle Pharmaceuticals’ Terminated Glioblastoma Trial: What Investors Need to Know NowDecember 18, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc. Common Stock (SHPH)December 16, 2025 | nasdaq.comShuttle Pharmaceuticals CFO Resigns, Interim CEO Steps InNovember 28, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHPH, MAAQ, GNTA, and LEXX Company DescriptionsGenenta Science NASDAQ:GNTA$0.63 0.00 (-0.16%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Lexaria Bioscience NASDAQ:LEXX$0.61 +0.00 (+0.02%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Mana Capital Acquisition NASDAQ:MAAQ$1.68 -0.11 (-6.15%) As of 05/14/2026Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Shuttle Pharmaceuticals NASDAQ:SHPH$0.67 +0.03 (+4.69%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
